Shuxuening Injection in the Treatment With Intravenous Thrombolysis in Patients With Ischemic Stroke (SHINY)

Inclusion Criteria:

• Age 18 or older;

• Diagnosed with acute ischemic stroke;

• Within 6 hours of onset;

• Having received or plan to undergo intravenous thrombolytic therapy;

• NIHISS score of 4 to 25 points at enrollment;

• Signed informed consent.

Exclusion Criteria:

• mRS score greater than 1 point before the onset;

• Receiving neuroprotective agents, such as edaravone, edaravone dextrocamphorol,butylphthalein, etc. after the onset;

• Bleeding or other pathological brain disorders, such as vascular malformations,tumors, abscesses, or other common non-ischemic brain diseases (such as multiplesclerosis), detected by CT/MRI;

• History of clotting disorders, systemic bleeding, thrombocytopenia, or neutropenia;

• Severe hepatic or renal insufficiency (severe hepatic insufficiency refers to theALT or AST levels above 3 times the upper limit of normal; severe renalinsufficiency refers to the creatinine levels above 2 times the upper limit ofnormal);

• Allergic to Shuxuening injection or preparations containing ginkgo biloba (ginkgobiloba extract);

• Women who are pregnant or breastfeeding, and women of childbearing age who have anegative pregnancy test but refuse to take effective contraceptive measures;

• Participation in another clinical trial with an experimental product during the last 30 days;

• Other participants deemed unsuitable for participation in this study by theinvestigator.